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Signalling by extracellular ATP has become a focus of hot
interest in virtually any field in biomedical sciences, from
developmental biology to neurophysiology, from kidney
diseases to ophthalmology and from osteoporosis to cancer
[1]. One of the fields that has lagged behind this, at times
tumultuous, development has been immunology. Although
reports from many laboratories have provided ample
demonstration that extracellular ATP and P2 receptors are
key players in the activation phases of the immune re-
sponse, the hypothesis that the purinergic system might be a
relevant pathway in host defense is surrounded by benign
skepticism in the immunological community. However, de-
spite this difficult acceptance, interest is slowly rising even
among immunologists, as witnessed by the steady increase
in the number of papers reporting on the effect of purinergic
agonists in many different immune-mediated responses.
Although the molecular details are often lacking a wealth
of observations emphasize the central role of extracellular
nucleotides in chemotaxis, cytokine secretion, cell fusion,
surface antigen shedding, intracellular pathogen killing and
inflammatory pain (see [2] for a recent review). Also
adenosine is enjoying a new life in immunology as novel
data support a crucial role of P1 receptors in the coor-
dinated tissue response in acute and chronic inflammation
under normoxic and hypoxic conditions [3]. Anti-inflam-
matory effects of adenosine seem to be mainly mediated via
the A2A receptor, while extracellular ATP as an immuno-
modulatory agent acts both at P2Y and P2X receptors.
Among the P2X receptors, the P2X7 subtype is gaining an
increasingly relevant role in the overall economy of cell
response to bacterial or host-derived noxious agents as we
learn more about the cellular integration of proinflamma-
tory signals by phagocyte sensors (whether located in the
plasma membrane or in the cytoplasm) and effector path-
ways [4, 5]. In fact, accumulating evidence shows that the
maturation and release of proinflammatory cytokines of the
interleukin (IL)-1 family are mediated by a caspase-1-
activating platform referred to as “inflammasome” which is
activated by pathogen- or host-derived factors, such as
muramyl dipeptide, uric acid crystals and calcium pyro-
phosphate [6]. These molecules directly interact with a
central component of the inflammasome known a NALP3/
CIAS1/cryopyrin. Recent data show that extracellular ATP
via the P2X7 receptor is one of the most potent physiolog-
ical stimuli for the inflammasome in a NALP3-dependent
fashion [7]. The very recent data implicating ATP in the
activation of the inflammasome nicely complement previ-
ous reports showing a crucial role of this nucleotide in the
maturation and release of key cytokines such as IL-1!, IL-
1" and IL-18 [4].
Furthermore, converging data from several laboratories
clearly show that chronic exposure of dendritic cells to low
ATP doses, as it may happen at sites of enduring low level
tissue damage by agents with low pathogenicity, has a
profound effect on dendritic cell differentiation, favouring
the development of a Th2-skewing dendritic cell phenotype
[8]. Finally, the demonstration that adenosine A2A recep-
tors have a non-redundant inhibitory role in preventing
inflammatory and immune cell activation nicely completes
the scenario illustrating the homeostatic function of puriner-
gic signalling in immunity [9]. Altogether, these exciting
observations bring purinergic signalling to the heart of im-
munity and inflammation.
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Any stressed or injured cell releases ATP via lytic or, most
likely, non-lytic pathways, thus generating a very early and
sensitive sign of cellular distress (“danger signal”). ATP
release quickly alerts the immune system of an impending
danger due to exogenous or endogenous causes. In this view,
purinergic receptors may function as sensors of danger
endowed with the ability to mould the immune response
according to the source, amount and duration of danger
signal/intracellular nucleotide release. An acute, massive
discharge of ATP into the extracellular space will act as a
potent co-stimulus for release of proinflammatory cytokines
of the IL-1 family and might even further enhance tissue
damage by exerting a direct cytotoxic effect. On the
contrary, a smaller but long lasting release will have a less
dramatic and more subtle effect by stimulating phagocyte
chemotaxis, upregulating chemokine receptors and driving
dendritic cell differentiation. As it is typical of any
homeostatic system, the activating arm will also turn on a
deactivating loop, represented in this case by the accumu-
lation of adenosine, which powerfully depresses immune
cell functions. Needless to say, the potential applications to
the therapy of inflammatory diseases are countless (Fig. 1).
Fig. 1 Purinergic signalling in the activation/deactivation of the
innate immune response. Pathogens release factors that activate innate
immunity either directly [e.g. lipopolysaccharide (LPS), muramyl
dipeptide (MDP), formyl-methionyl-leucyl-phenylalanine (fMLP)] or
indirectly by causing injury or distress of host cells (e.g. ATP).
Bacterial factors, which are also known as “exogenous danger
signals”, recruit and stimulate tissue macrophages, dendritic cells
(DC) and polymorphonuclear leukocytes (PMN). Activated inflam-
matory cells are shown in red. Extracellular ATP, which accumulates
at sites of inflammation and may be considered an “endogenous
danger signal”, modulates the activity of pathogen-derived factors in
different ways (red arrows). For example, ATP can exert a synergistic,
proinflammatory effect, by increasing cytokine release (e.g. IL-1b, IL-
18, TNF!) from endotoxin-primed mononuclear phagocytes, or by
stimulating secretion of bactericidal factors (e.g. lysozyme) and
synthesis of reactive oxygen species (ROS) by PMN. These responses
are mediated via the P2X7 as well as other P2 receptors. On the DC,
the effect of extracellular ATP in conjunction with bacterial-derived
factors is more complex as while high concentrations cause a strong
proinflammatory activation, chronic exposure to low concentrations
drive DC maturation toward a phenotype favouring the development
of a Th2 response. The DC modulatory effects of ATP are mainly
mediated via the P2Y11 receptor. Thus, LPS-maturated and ATP-
stimulated DC show a high release of anti-inflammatory cytokines,
such as IL-10 and IL-Ra, and of chemokines driving a preferential
recruitment of Th2 lymphocytes (such as CCL22). Vice versa, LPS-
maturated and ATP-stimulated DC downmodulate secretion of IL-1",
IL-6, IL-12, TNF!, and of chemokines, such as CCL5 and CXCL10,
that preferentially recruit Th1 cells. In the extracellular milieu ATP is
degraded by plasma membrane ecto-ATPases (such as CD39) and
generates adenosine, which by acting at A2A receptors has a profound
downmodulatory role on inflammation and immunity as a whole
(green lines)
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